Drugs / Immunoglobulins, Intravenous
Immunoglobulins, Intravenous
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02308982 Comparator | Jan 2016 → Sep 2022 | encephalitis | University of Oxford | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunoglobulins, Intravenous | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02308982 ↗ |
| Known as | intravenous immunoglobulin | “OBJECTIVE: To investigate whether intravenous immunoglobulin (IVIG) improves neurological outcomes in children with encephalitis when administered early.” PMID 37945292 ↗ Nov 2023 |
| Known as | IVIG | “OBJECTIVE: To investigate whether intravenous immunoglobulin (IVIG) improves neurological outcomes in children with encephalitis when administered early.” PMID 37945292 ↗ Nov 2023 |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin treatment” NCT02308982 ↗ |
| Route | Intravenous | “Intravenous immunoglobulin: 1g/kg per day for 2 consecutive days” NCT02308982 ↗ |